BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
How to identify animal tracks, burrows and other signs of wildlife in your neighborhood - 2UPM Adhesive Materials plans new facility near New Delhi, India
- 3Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
- 4The German series proving subtitles can be sexy — and wildly addictive
- 5Brexit's Effect on New York's Ascent as a Main Monetary Center
- Audits of 6 European Busssiness Class Flights
- Which European palace do you fantasy about visiting? Vote!
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Death toll from floods in Afghanistan rises to 61
- Invigorating Spots To Go Kayaking All over The Planet
- SF Chinatown's historic Empress of China building being revived into cultural campus
- The Ascent of the Kona SUV: How Hyundai's Reduced Hybrid Is Vanquishing the Streets
- Landslides triggered by heavy rainfall kill at least 20 people in Tanzania
- Remote Work Survival manual: Helping Efficiency at Home
